Saturday 17 October 2026
Export DXCM’s income statement to Excel — free account
DexCom, Inc.
DXCM Healthcare Medical Devices
DexCom, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.7 billion, up 15.6% from fiscal 2024. In the quarter to June 2026, revenue grew 13.1%, EPS grew 41.3%, free cash flow fell 11.7% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for ten consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
86.06
1.65
−1.88%
Follow DXCM
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
8 | 9 | 8 | 6 |
+8 more TTM periods Free account |
| 38.49% | 35.62% | 34.50% | 30.63% | ||
| 14.51% | 13.90% | 13.04% | 10.40% | ||
ROIC |
37.13% | 36.21% | 28.66% | 75.49% | |
Return on Tangible Assets |
30.24% | 25.37% | 24.24% | 21.48% | |
Average Days of Receivables |
92.38 | 82.47 | 95.21 | 89.68 | |
Free Cash Flow per Share |
3.68 | 3.71 | 2.76 | 2.72 | |
Free Cash Flow |
1,405.00 | 1,429.40 | 1,077.20 | 1,061.90 | |
Capital Expenditures |
(343.70) | (353.10) | (363.50) | (386.20) | |
| Other line items | |||||
Cash ROIC |
24.18% | 21.61% | 18.00% | 14.57% | |
Accounts Receivable Turnover |
3.81 | 4.29 | 4.20 | 4.28 | |
Accounts Payable Turnover |
0.90 | 0.99 | 1.05 | 1.05 | |
Inventory Turnover |
2.88 | 3.01 | 3.18 | 3.11 | |
Average Days of Payables |
428.95 | 408.14 | 381.46 | 381.07 | |
Days of Inventory on Hand |
142.18 | 136.50 | 123.45 | 119.13 | |
Tax Rate |
(0.22) | (0.23) | (0.23) | (0.25) | |
Research and Development Expense of Revenue |
12.15% | 12.44% | 12.85% | 13.07% | |
Selling, General and Administrative Expense of Revenue |
27.39% | 27.62% | 27.69% | 28.72% | |
Share Based Compensation of Revenue |
3.27% | 3.50% | 3.42% | 3.72% | |
Operating CF/Net income |
1.75 | 1.92 | 1.72 | 2.01 | |
Depreciation/Fixed assets |
0.17 | 0.17 | 0.16 | 0.17 | |
Capex/Depreciation |
(1.30) | (1.36) | (1.44) | (1.58) | |
Revenue per Share |
13.00 | 12.51 | 11.95 | 11.55 | |
Operating CF per Share |
4.58 | 4.63 | 3.69 | 3.70 | |
Capex per Share |
(0.90) | (0.92) | (0.93) | (0.99) | |
Capex to Sales |
0.07 | 0.07 | 0.08 | 0.09 |
Columns are period end dates